Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 33-49 , February 2009

Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance

References 

  1. Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Current Medicinal Chemistry. 1999;6:757–773
  2. Lambert DM, Muccioli GG. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Current Opinion in Clinical Nutrition and Metabolic Care. 2007;10:735–744
  3. Petrosino S & Di Marzo V. Anandamide and other acylethanolamides. In Lajtha A (ed.). Neural lipids. Handbook of neurochemistry and molecular neurobiology, vol. 8, Heidelberg: Springer, in press.
  4. Schuel H, Burkman LJ, Lippes J, et al. N-Acylethanolamines in human reproductive fluids. Chemistry and Physics of Lipids. 2002;121:211–227
  5. LoVerme J, La Rana G, Russo R, et al. The search for the palmitoylethanolamide receptor. Life Sciences. 2005;77:1685–1698
  6. Capasso R, Matias I, Lutz B, et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology. 2005;129:941–951
  7. Matias I, Gonthier MP, Petrosino S, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. British Journal of Pharmacology. 2007;152:676–690
  8. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57:1140–1155
  9. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut. 2006;55:1373–1376
  10. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British Journal of Pharmacology. 2008;153:263–270
  11. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Current Opinion in Pharmacology. 2007;7:575–582
  12. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129:437–543
  13. Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. British Journal of Pharmacology. 2006;148:191–199
  14. Guagnini F, Valenti M, Mukenge S, et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut. 2006;55:946–953
  15. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British Journal of Pharmacology. 2007;152:583–593
  16. Geppetti P, Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. British Journal of Pharmacology. 2004;141:1313–1320
  17. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. European Journal of Pharmacology. 2004;500:231–241
  18. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacology & Therapeutics. 2007;114:13–33
  19. Ross RA. Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology. 2003;140:790–801
  20. Mang CF, Erbelding D, Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. British Journal of Pharmacology. 2001;134:161–167
  21. McVey DC, Schmid PC, Schmid HH, et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). The Journal of Pharmacology and Experimental Therapeutics. 2003;304:713–722
  22. Ahern GP. Activation of TRPV1 by the satiety factor oleoylethanolamide. The Journal of Biological Chemistry. 2003;278:30429–30434
  23. Wang X, Miyares RL, Ahern GP. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. The Journal of Physiology. 2005;564:541–547
  24. Brown AJ. Novel cannabinoid receptors. British Journal of Pharmacology. 2007;152:567–575
  25. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. British Journal of Pharmacology. 2008;153(Suppl. 1):S76–S81
  26. Baker D, Pryce G, Davies WL, et al. In silico patent searching reveals a new cannabinoid receptor. Trends in Pharmacological Sciences. 2006;27:1–4
  27. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology. 2007;152:1092–1101
  28. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology. 2007;152:576–582
  29. Mansén A, Guardiola-Diaz H, Rafter J, et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochemical and Biophysical Research Communications. 1996;222:844–851
  30. Yamazaki K, Shimizu M, Okuno M, et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells–phosphorylated RXR alpha is a critical target for colon cancer management. Gut. 2007;56:1557–1563
  31. Linard C, Grémy O, Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. The Journal of Pharmacology and Experimental Therapeutics. 2008;324:911–920
  32. Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. Journal of Lipid Research. 2007;48:2725–2735
  33. Sun Y, Alexander SP, Garle MJ, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. British Journal of Pharmacology. 2007;152:734–743
  34. Aviello G, Matias I, Capasso R, et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. Journal of Molecular Medicine. 2008;86:413–422
  35. Di Marzo V, Capasso R, Matias I, et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. British Journal of Pharmacology. 2008;153:1272–1280
  36. Fu J, Astarita G, Gaetani S, et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. The Journal of Biological Chemistry. 2007;282:1518–1528
  37. Sun YX, Tsuboi K, Okamoto Y, et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. The Biochemical Journal. 2004;380:749–756
  38. Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology. 2003;125:765–774
  39. D'Argenio G, Valenti M, Scaglione G, et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. The FASEB Journal. 2006;20:568–570
  40. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:2238–2242
  41. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. British Journal of Pharmacology. 2001;134:563–570
  42. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. The Journal of Clinical Investigation. 2004;113:1202–1209
  43. Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. The Journal of Pharmacology and Experimental Therapeutics. 2005;313:352–358
  44. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. The Journal of Biological Chemistry. 2001;276:35552–35557
  45. Wei BQ, Mikkelsen TS, McKinney MK, et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. The Journal of Biological Chemistry. 2006;281:36569–36578
  46. Dembiński A, Warzecha Z, Ceranowicz P, et al. Cannabinoids in acute gastric damage and pancreatitis. Journal of Physiology and Pharmacology. 2006;57(Suppl. 5):137–154
  47. Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. British Journal of Pharmacology. 2002;135:1598–1606
  48. MacNaughton WK, Van Sickle MD, Keenan CM, et al. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2004;286:G863–G871
  49. Izzo AA, Capasso F. Marijuana for cholera therapy. Trends in Pharmacological Sciences. 2006;27:7–8
  50. Pertwee RG, Fernando SR, Nash JE, et al. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. British Journal of Pharmacology. 1996;118:2199–2205
  51. Izzo AA, Mascolo N, Borrelli F, et al. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. British Journal of Pharmacology. 1998;124:1363–1368
  52. Storr M, Sibaev A, Marsicano G, et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2004;286:G110–G1177
  53. Mulè F, Amato A, Baldassano S, et al. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacological Research. 2007;56:185–192
  54. Abalo R, Rivera AJ, Vera G, et al. Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscle-myenteric plexus preparations. Neuroscience Letters. 2005;383:176–181
  55. Baldassano S, Serio R, Mule' F. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. European Journal of Pharmacology. 2008;582:132–138
  56. Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology. 1999;38:1289–1297
  57. Smid SD, Bjorklund CK, Svensson KM, et al. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. European Journal of Pharmacology. 2007;575:168–176
  58. Mascolo N, Izzo AA, Ligresti A, et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. The FASEB Journal. 2002;16:1973–1975
  59. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology. 2002;123:227–234
  60. Izzo AA, Capasso R, Pinto L, et al. Effect of vanilloid drugs on gastrointestinal transit in mice. British Journal of Pharmacology. 2001;132:1411–1416
  61. Yuece B, Sibaev A, Broedl UC, et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterology and Motility. 2007;19:744–753
  62. Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. British Journal of Pharmacology. 2008;154:1001–1008
  63. Capasso R, Izzo AA, Fezza F, et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British Journal of Pharmacology. 2001;134:945–950
  64. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125:677–687
  65. Patsos HA, Hicks DJ, Dobson RR, et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut. 2005;54:1741–1750
  66. Joseph J, Niggemann B, Zaenker KS, et al. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy. 2004;53:723–728
  67. Izzo AA, Aviello G, Petrosino S, et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. Journal of Molecular Medicine. 2008;86:89–98
  68. De Petrocellis L, Bisogno T, Ligresti A, et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundamental & Clinical Pharmacology. 2002;16:297–302
  69. D'Argenio G, Petrosino S, Gianfrani C, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. Journal of Molecular Medicine. 2007;85:523–530
  70. Izzo AA. The cannabinoid CB2 receptor: a good friend in the gut. Neurogastroenterology and Motility. 2007;19:704–708
  71. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2006;291:G364–G371
  72. Storr MA, Keenan CM, Emmerdinger D, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB(1) and CB (2) receptors. Journal of Molecular Medicine. 2008;86:925–936
  73. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterology and Motility. 2006;18:949–956
  74. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Molecular Pharmacology. 2005;67:15–19
  75. Suardíaz M, Estivill-Torrús G, Goicoechea C, et al. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain. 2007;133:99–110
  76. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism: TEM. 2007;18:27–37
  77. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology. 1999;143:315–317
  78. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology. 2001;134:1151–1154
  79. Proulx K, Cota D, Castañeda TR, et al. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2005;289:R729–R737
  80. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. The Journal of Neuroscience. 2002;22:9612–9617
  81. Lo Verme J, Gaetani S, Fu J, et al. Regulation of food intake by oleoylethanolamide. Cellular and Molecular Life Sciences: CMLS. 2005;62:708–716
  82. Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414:209–212
  83. Nielsen MJ, Petersen G, Astrup A, et al. Food intake is inhibited by oral oleoylethanolamide. Journal of Lipid Research. 2004;45:1027–1029
  84. Petersen G, Sørensen C, Schmid PC, et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochimica et biophysica acta. 2006;1761:143–150
  85. Serrano A, Del Arco I, Javier Pavón F, et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology. 2008;54:226–234
  86. Oveisi F, Gaetani S, Eng KT, et al. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacological Research. 2004;49:461–466
  87. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90–93
  88. Terrazzino S, Berto F, Dalle Carbonare M, et al. Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. The FASEB Journal. 2004;18:1580–1582
  89. LoVerme J, Guzmán M, Gaetani S, et al. Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue. The Journal of Biological Chemistry. 2006;281:22815–22818
  90. Fu J, Kim J, Oveisi F, et al. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2008 Apr 23;295:R45–R50
  91. Artmann A, Petersen G, Hellgren LI, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochimica et biophysica acta. 2008;1781:200–212
  92. Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Molecular and Cellular Endocrinology. 2008;286:S66–S78
  93. Cani PD, Montoya ML, Neyrinck AM, et al. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. The British Journal of Nutrition. 2004;92:757–761
  94. Yang Y, Chen M, Georgeson KE, et al. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2007;292:R235–R341
  95. Gonçalves P, Araújo JR, Azevedo I, et al. Lack of a significant effect of cannabinoids upon the uptake of 2-deoxy-D-glucose by Caco-2 cells. Pharmacology. 2008;82:30–37
  96. Després JP, Lemieux I, Alméras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. International Journal of Obesity (2005). 2006;30(Suppl. 1):S44–S52
  97. Côté M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity (2005). 2007;31:692–699
  98. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053–5060
  99. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2003;284:R345–R353
  100. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. The Journal of Clinical Investigation. 2007;117:13–23
  101. Capasso R, Izzo AA. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. Journal of Neuroendocrinology. 2008;20(Suppl. 1):39–46
  102. Burdyga G, Lal S, Varro A, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. The Journal of Neuroscience. 2004;24:2708–2715
  103. Pazos MR, Tolón RM, Benito C, et al. Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. The Journal of Histochemistry and Cytochemistry. 2008;56:511–516

PII: S1521-690X(08)00121-8

doi: 10.1016/j.beem.2008.10.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 33-49 , February 2009

Article Tools

* Image Usage & Resolution